{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T23:43:48Z","timestamp":1768002228469,"version":"3.49.0"},"reference-count":117,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T00:00:00Z","timestamp":1651190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Audiology Research"],"abstract":"<jats:p>(1) Background: The purpose of this article is to review pharmacological treatments for COVID-19 (currently approved by the EMA (European Medical Agency) and FDA (Food and Drug Administration)) and highlight their potential audio-vestibular side-effects as an ototoxic adverse reaction. (2) Methods: Review of the available literature in the scientific databases PubMed, ResearchGate, Scopus, and ScienceDirect, and in summaries of product data sheets. (3) Results: In accordance with EBM (evidence-based medicine) the treatment of COVID-19 by using lopinavir\/ritonavir, chloroquine and hydroxychloroquine, azithromycin, favipiravir, amantadine, oseltamivir, and ivermectin is no longer recommended for patients suffering from COVID-19 due to a lack of clinical data, publications, and recommendations. There were 39 publications and 15 summaries of product characteristics (as other sources of data) which were also used in this analysis. Adverse events could be permanent or disappear over time. Following treatment for COVID-19, the most frequent adverse audio-vestibular reactions reported in clinical trials and publications in the area of audiology and otorhinolaryngology were: dizziness, blurry vision with dizziness, nasopharyngitis, dysgeusia, and tinnitus. As far as vaccines are concerned, dizziness as an ototoxic effect was uncommon and occurs only in hypersensitive people who experience anaphylactic shock. (4) Conclusions: The ototoxicity of the drugs discussed here does not have as severe symptoms as the drugs used in the treatment of COVID-19 in 2020 (e.g., hydroxychloroquine), and relates mainly to disorders of the vestibulocochlear system. However, there is still a need to monitor ototoxic side-effects because of potential interactions with other ototoxic drugs. Many of the drugs approved by EMA and FDA are new, and not every side-effect is known.<\/jats:p>","DOI":"10.3390\/audiolres12030025","type":"journal-article","created":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T16:49:57Z","timestamp":1651250997000},"page":"224-248","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Adverse Audio-Vestibular Effects of Drugs and Vaccines Used in the Treatment and Prevention of COVID-19: A Review"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3340-1698","authenticated-orcid":false,"given":"Magdalena B.","family":"Skarzynska","sequence":"first","affiliation":[{"name":"Institute of Sensory Organs, 05-830 Warsaw, Poland"},{"name":"Center of Hearing and Speech Medincus, 05-830 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Matusiak","sequence":"additional","affiliation":[{"name":"World Hearing Center, Oto-Rhino-Laryngology Surgery Department, Institute of Physiology and Pathology of Hearing, 05-830 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4978-1915","authenticated-orcid":false,"given":"Piotr H.","family":"Skarzynski","sequence":"additional","affiliation":[{"name":"Institute of Sensory Organs, 05-830 Warsaw, Poland"},{"name":"World Hearing Center, Department of Teleaudiology of Hearing, Institute of Physiology and Pathology of Hearing, 05-830 Warsaw, Poland"},{"name":"Heart Failure and Cardiac Rehabilitation Department, Faculty of Medicine, Medical University of Warsaw, 03-242 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,29]]},"reference":[{"key":"ref_1","unstructured":"(2022, January 19). Hospitalized Adults: Therapeutic Management, Available online: https:\/\/www.covid19treatmentguidelines.nih.gov\/management\/clinical-management\/hospitalized-adults--therapeutic-management\/."},{"key":"ref_2","unstructured":"Cennimo, D. (2022, February 20). Coronavirus Disease 2019 (COVID-19) Treatment & Management: Approach Considerations, Prevention, Antiviral Agents. Available online: https:\/\/emedicine.medscape.com\/article\/2500114-treatment."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"(2021). An EUA for Bamlanivimab\u2014A Monoclonal Antibody for COVID-19. JAMA, 325, 880\u2013881.","DOI":"10.1001\/jama.2020.24415"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa2029849","article-title":"SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with COVID-19","volume":"384","author":"Chen","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19","volume":"384","author":"Kalil","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_6","unstructured":"Regeneron Pharmaceuticals Inc. (2022, January 19). Regeneron\u2019s COVID-19 Outpatient Trial Prospectively Demonstrates That REGN-COV2 Antibody Cocktail Significantly Reduced Virus Levels and Need for Further Medical Attention. Available online: https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/regenerons-covid-19-outpatient-trial-prospectively-demonstrates\/."},{"key":"ref_7","unstructured":"(2022, February 20). Casirivimab and Imdevimab. Available online: https:\/\/www.regeneron.com\/medicines\/casirivimab-imdevimab."},{"key":"ref_8","unstructured":"US Food and Drug Administration (2022, January 19). Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibodies-treatment-covid-19."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the Treatment of COVID-19\u2013Final Report","volume":"383","author":"Beigel","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1056\/NEJMoa2015301","article-title":"Remdesivir for 5 or 10 Days in Patients with Severe COVID-19","volume":"383","author":"Goldman","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/jama.2020.16349","article-title":"Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial","volume":"324","author":"Spinner","year":"2020","journal-title":"JAMA"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in Adults with Severe COVID-19: A Randomised, Double-Blind, Placebo-Controlled, Multicentre Trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/S2213-2600(20)30503-8","article-title":"Dexamethasone in Hospitalised Patients with COVID-19: Addressing Uncertainties","volume":"8","author":"Matthay","year":"2020","journal-title":"Lancet. Respir. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"59","DOI":"10.7874\/jao.2017.00360","article-title":"Ototoxicity: A Challenge in Diagnosis and Treatment","volume":"22","author":"Ganesan","year":"2018","journal-title":"J. Audiol. Otol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1055\/s-0039-1684042","article-title":"Monitoring Protocols for Cochlear Toxicity","volume":"40","author":"Lord","year":"2019","journal-title":"Semin. Hear."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1055\/s-0039-1684044","article-title":"Pediatric Ototoxicity: Current Trends and Management","volume":"40","author":"Fligor","year":"2019","journal-title":"Semin. Hear."},{"key":"ref_17","unstructured":"Durrant, J. (2022, February 16). American Academy of Audiology Position Statement and Clinical Practice Guidelines: Ototoxicity Monitoring. Available online: https:\/\/audiology-web.s3.amazonaws.com\/migrated\/OtoMonGuidelines.pdf_539974c40999c1.58842217.pdf."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1002\/phar.2478","article-title":"Drug-Induced Ototoxicity: A Comprehensive Review and Reference Guide","volume":"40","author":"Rizk","year":"2020","journal-title":"Pharmacotherapy"},{"key":"ref_19","first-page":"7946","article-title":"Drugs Inducing Hearing Loss, Tinnitus, Dizziness and Vertigo: An Updated Guide","volume":"24","author":"Altissimi","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Dusan, M., Milan, S., and Nikola, D. (2021). COVID-19 Caused Hearing Loss. Eur. Arch. Otorhinolaryngol., 1\u201310.","DOI":"10.1007\/s00405-021-06951-x"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"McIntyre, K.M., Favre, N.M., Kuo, C.C., and Carr, M.M. (2021). Systematic Review of Sensorineural Hearing Loss Associated With COVID-19 Infection. Cureus, 13.","DOI":"10.7759\/cureus.19757"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s43856-021-00044-w","article-title":"Direct SARS-CoV-2 Infection of the Human Inner Ear May Underlie COVID-19-Associated Audiovestibular Dysfunction","volume":"1","author":"Jeong","year":"2021","journal-title":"Commun. Med."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Thrane, J.F., Britze, A., and Fjaeldstad, A.W. (2022, February 20). Incidence and Duration of Self-Reported Hearing Loss and Tinnitus in a Cohort of COVID-19 Patients with Sudden Chemosensory Loss: A STROBE Observational Study\u2013ScienceDirect. Available online: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1879729621002246.","DOI":"10.1016\/j.anorl.2021.07.012"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jgar.2020.09.030","article-title":"Ototoxicity Prevention during the SARS-CoV-2 (COVID-19) Emergency","volume":"23","author":"Ciorba","year":"2020","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"20587384211027372","DOI":"10.1177\/20587384211027373","article-title":"SARS-CoV-2 (COVID-19) and Audio-Vestibular Disorders","volume":"35","author":"Fancello","year":"2021","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2058738420941754","DOI":"10.1177\/2058738420941754","article-title":"Don\u2019t Forget Ototoxicity during the SARS-CoV-2 (Covid-19) Pandemic!","volume":"34","author":"Ciorba","year":"2020","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1001\/jamaoto.2021.0869","article-title":"Preliminary Analysis of Association Between COVID-19 Vaccination and Sudden Hearing Loss Using US Centers for Disease Control and Prevention Vaccine Adverse Events Reporting System Data","volume":"147","author":"Formeister","year":"2021","journal-title":"JAMA Otolaryngol. Head Neck Surg."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.rdc.2015.08.002","article-title":"Corticosteroids: Mechanisms of Action in Health and Disease","volume":"42","author":"Ramamoorthy","year":"2016","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Ahmed, M.H., and Hassan, A. (2020). Dexamethasone for the Treatment of Coronavirus Disease (COVID-19): A Review. SN Compr. Clin. Med., 1\u201310.","DOI":"10.1007\/s42399-020-00610-8"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2344\/0003-3006-60.1.25","article-title":"Basic and Clinical Pharmacology of Glucocorticosteroids","volume":"60","author":"Becker","year":"2013","journal-title":"Anesth. Prog."},{"key":"ref_32","first-page":"443","article-title":"A Different Look at Corticosteroids","volume":"58","author":"Zoorob","year":"1998","journal-title":"Am. Fam. Physician"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejcdt.2012.10.019","article-title":"Dexamethasone as Adjunctive Therapy for Treatment of Varicella Pneumonia","volume":"61","author":"Saraya","year":"2012","journal-title":"Egypt. J. Chest Dis. Tuberc."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000362724","article-title":"One Hormone, Two Actions: Anti- and pro-Inflammatory Effects of Glucocorticoids","volume":"22","author":"Cidlowski","year":"2015","journal-title":"Neuroimmunomodulation"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1126\/science.1116480","article-title":"Structure of SARS Coronavirus Spike Receptor-Binding Domain Complexed with Receptor","volume":"309","author":"Li","year":"2005","journal-title":"Science"},{"key":"ref_36","first-page":"343","article-title":"AhR and IDO1 in Pathogenesis of Covid-19 and the \u201cSystemic AhR Activation Syndrome:\u201d A Translational Review and Therapeutic Perspectives","volume":"38","author":"Turski","year":"2020","journal-title":"Restor. Neurol. Neurosci."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"RECOVERY Collaborative Group, Horby, P., Lim, W.S., Emberson, J.R., Mafham, M., Bell, J.L., Linsell, L., Staplin, N., Brightling, C., and Ustianowski, A. (2021). Dexamethasone in Hospitalized Patients with COVID-19. N. Engl. J. Med., 384, 693\u2013704.","DOI":"10.1056\/NEJMoa2021436"},{"key":"ref_38","unstructured":"Czarska-Thorley, D. (2022, January 19). Ema Endorses Use of Dexamethasone in COVID-19 Patients on Oxygen or Mechanical Ventilation. Available online: https:\/\/www.ema.europa.eu\/en\/news\/ema-endorses-use-dexamethasone-covid-19-patients-oxygen-mechanical-ventilation."},{"key":"ref_39","unstructured":"Boehringer Ingelheim RCV GmbH & Co KG. (2021). Pfizer Health AB Kineret\u2013Summary of Product Characteristics, Boehringer Ingelheim RCV GmbH & Co KG."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1038\/s41591-021-01499-z","article-title":"Early Treatment of COVID-19 with Anakinra Guided by Soluble Urokinase Plasminogen Receptor Plasma Levels: A Double-Blind, Randomized Controlled Phase 3 Trial","volume":"27","author":"Kyriazopoulou","year":"2021","journal-title":"Nat. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1186\/s13054-020-03020-3","article-title":"Exploring Pharmacological Approaches for Managing Cytokine Storm Associated with Pneumonia and Acute Respiratory Distress Syndrome in COVID-19 Patients","volume":"24","author":"Convertino","year":"2020","journal-title":"Crit. Care"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e00072-20","DOI":"10.1128\/CMR.00072-20","article-title":"Convalescent Plasma Therapy for COVID-19: State of the Art","volume":"33","author":"Focosi","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jcyt.2020.08.009","article-title":"Antibodies at Work in the Time of Severe Acute Respiratory Syndrome Coronavirus 2","volume":"23","author":"Sajna","year":"2021","journal-title":"Cytotherapy"},{"key":"ref_44","unstructured":"(2022, January 19). FDA Issues EUA for Bamlanivimab to Treat COVID-19. Available online: http:\/\/www.pharmacist.com\/Pharmacy-News\/fda-issues-eua-for-bamlanivimab-to-treat-covid-19."},{"key":"ref_45","unstructured":"(2022, January 19). Bamlanivimab and Etesevimab Emergency Use Authorization (EUA) for COVID-19. Available online: https:\/\/www.covid19.lilly.com\/bam-ete\/hcp."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa2102685","article-title":"Bamlanivimab plus Etesevimab in Mild or Moderate COVID-19","volume":"385","author":"Dougan","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_47","unstructured":"(2022, January 19). Casirivimab, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK572124\/."},{"key":"ref_48","unstructured":"(2022, January 19). Imdevimab, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK572065\/."},{"key":"ref_49","unstructured":"REGEN-COV\u00ae (2022, January 19). Casirivimab and Imdevimab. Available online: https:\/\/www.regencov.com\/hcp."},{"key":"ref_50","unstructured":"US Food and Drug Administration (2022, January 19). Coronavirus (COVID-19) Update: Daily Roundup, March 24, 2020, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-daily-roundup-march-24-2020."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1056\/NEJMoa2108163","article-title":"REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19","volume":"385","author":"Weinreich","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_52","first-page":"1491","article-title":"Interleukin-6 Receptor Antagonists in Critically Ill Patients with COVID-19","volume":"385","author":"Gordon","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_53","unstructured":"COVID Research (2022, January 19). A Year of Scientific Milestones. Available online."},{"key":"ref_54","unstructured":"(2022, January 19). RoActemra. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/roactemra."},{"key":"ref_55","unstructured":"(2022, January 19). Roche Registration. GmbH Roactemra\u2013Summary of Product Characteristics. Available online: https:\/\/www.rocheresources.co.uk\/content\/dam\/hcp-portals\/uk2\/documents\/roactemra\/RoActemra_product_summary.pdf."},{"key":"ref_56","unstructured":"(2022, January 19). Kevzara 150 Mg Solution for Injection in Pre-Filled Syringe\u2013Summary of Product Characteristics (SmPC)\u2013(Emc). Available online: https:\/\/www.medicines.org.uk\/emc\/product\/762\/smpc#gref."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1056\/NEJMoa2028836","article-title":"Efficacy of Tocilizumab in Patients Hospitalized with COVID-19","volume":"383","author":"Stone","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_58","unstructured":"AstraZeneca (2022, January 19). Tixagevimab Co-Packaged with Cilgavimab\u2013Fact Sheet For Healthcare Providers: Emergency Use Authorization For Evusheld, Available online: https:\/\/www.fda.gov\/media\/154701\/download."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"S810","DOI":"10.1093\/ofid\/ofab466.1646","article-title":"LB5. PROVENT: Phase 3 Study of Efficacy and Safety of AZD7442 (Tixagevimab\/Cilgavimab) for Pre-Exposure Prophylaxis of COVID-19 in Adults","volume":"8","author":"Levin","year":"2021","journal-title":"Open Forum Infect. Dis."},{"key":"ref_60","unstructured":"GlaxoSmithKline Manufacturing S.p.A. (2022, January 19). Sotrovimab\u2013Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xevudy-epar-product-information_en.pdf."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa2107934","article-title":"Early Treatment for COVID-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab","volume":"385","author":"Gupta","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_62","unstructured":"Merck & Co., Inc. (2022). Molnupiravir\u2014Fact Sheet for Healthcare Providers: Emergency Use Authorization, Merck & Co., Inc."},{"key":"ref_63","unstructured":"(2022, February 17). Covid-19: Molnupiravir Reduces Risk of Hospital Admission or Death by 50% in Patients at Risk, MSD Reports. BMJ. Available online: https:\/\/www.bmj.com\/content\/375\/bmj.n2422."},{"key":"ref_64","unstructured":"(2022, January 19). Pfizer Labs Paxlovid: Fact Sheet For Healthcare Providers: Emergency Use Authorization, Available online: https:\/\/www.fda.gov\/media\/155050\/download."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"8","DOI":"10.7150\/ijbs.52569","article-title":"Current Advances in the Development of SARS-CoV-2 Vaccines","volume":"17","author":"Awadasseid","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"198114","DOI":"10.1016\/j.virusres.2020.198114","article-title":"COVID-19 Vaccine: A Comprehensive Status Report","volume":"288","author":"Kaur","year":"2020","journal-title":"Virus Res."},{"key":"ref_67","unstructured":"(2022, January 19). AstraZeneca\u2019s COVID-19 Vaccine Authorised for Emergency Supply in the UK. Available online: https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2020\/astrazenecas-covid-19-vaccine-authorised-in-uk.html."},{"key":"ref_68","unstructured":"(2022, January 19). CDC Ensuring the Safety of COVID-19 Vaccines in the United States, Available online: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/safety.html."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the MRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 MRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1093\/qjmed\/hcab210","article-title":"The Reversible Tinnitus and Cochleopathy Followed First-Dose AstraZeneca COVID-19 Vaccination","volume":"114","author":"Tseng","year":"2021","journal-title":"QJM"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ijid.2021.10.025","article-title":"Sudden Sensorineural Hearing Loss after COVID-19 Vaccination","volume":"113","author":"Jeong","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"ref_73","unstructured":"Pfizer (2022, January 19). COMIRNATY\u00ae|Pfizer UK. Available online: https:\/\/www.pfizer.co.uk\/products\/prescription-medicines\/comirnaty."},{"key":"ref_74","unstructured":"(2022, January 19). Summary of Product Characteristics for Spikevax, Available online: https:\/\/www.gov.uk\/government\/publications\/regulatory-approval-of-covid-19-vaccine-moderna\/information-for-healthcare-professionals-on-covid-19-vaccine-moderna."},{"key":"ref_75","unstructured":"(2022, January 19). Regulatory Approval of Vaxzevria (Previously COVID-19 Vaccine AstraZeneca), Available online: https:\/\/www.gov.uk\/government\/publications\/regulatory-approval-of-covid-19-vaccine-astrazeneca."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1056\/NEJMoa2105290","article-title":"Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 NCoV-19) COVID-19 Vaccine","volume":"385","author":"Falsey","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_77","unstructured":"Novavax CZ a.s. (2022, January 19). Nuvaxovid-Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/nuvaxovid-epar-product-information_en.pdf?_x_tr_sl=en&_x_tr_tl=fi&_x_tr_hl=fi&_x_tr_pto=sc."},{"key":"ref_78","unstructured":"(2022, January 19). Dexamethasone in Hospitalized Patients with Covid-19. Available online: https:\/\/www.nejm.org\/doi\/full\/10.1056\/nejmoa2021436."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S2213-2600(20)30556-7","article-title":"Effect of Anakinra versus Usual Care in Adults in Hospital with COVID-19 and Mild-to-Moderate Pneumonia (CORIMUNO-ANA-1): A Randomised Controlled Trial","volume":"9","author":"Tharaux","year":"2021","journal-title":"Lancet Resp. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(22)00163-5","article-title":"Casirivimab and Imdevimab in Patients Admitted to Hospital with COVID-19 (RECOVERY): A Randomised, Controlled, Open-Label, Platform Trial","volume":"399","author":"Abani","year":"2022","journal-title":"Lancet"},{"key":"ref_81","unstructured":"(2022, January 19). Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19. Available online: https:\/\/www.nejm.org\/doi\/full\/10.1056\/nejmoa2109682."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"(2021). Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N. Engl. J. Med., 384, 1491\u20131502.","DOI":"10.1056\/NEJMoa2100433"},{"key":"ref_83","unstructured":"(2022, January 19). Tocilizumab and Remdesivir in Hospitalized Patients with Severe COVID-19 Pneumonia: A Randomized Clinical Trial, Available online: https:\/\/pubmed.ncbi.nlm.nih.gov\/34609549\/."},{"key":"ref_84","unstructured":"(2022, January 19). Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. Available online: https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2030340."},{"key":"ref_85","unstructured":"(2022, January 19). Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. Available online: https:\/\/www.nejm.org\/doi\/full\/10.1056\/nejmoa2028836."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ijid.2021.04.047","article-title":"Side Effects of BNT162b2 MRNA COVID-19 Vaccine: A Randomized, Cross-Sectional Study with Detailed Self-Reported Symptoms from Healthcare Workers","volume":"106","author":"Kadali","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1056\/NEJMoa2110475","article-title":"Safety of the BNT162b2 MRNA Covid-19 Vaccine in a Nationwide Setting","volume":"385","author":"Barda","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_88","unstructured":"(2022, January 19). Safety and Efficacy of the BNT162b2 MRNA Covid-19 Vaccine. Available online: https:\/\/www.nejm.org\/doi\/full\/10.1056\/nejmoa2034577."},{"key":"ref_89","unstructured":"(2022, January 19). Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S. Available online: https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2117608."},{"key":"ref_90","unstructured":"(2022, April 27). Safety and Efficacy of the ChAdOx1 NCoV-19 Vaccine (AZD1222) against SARS-CoV-2: An Interim Analysis of Four Randomised Controlled Trials in Brazil, South Africa, and the UK. Available online: https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(20)32661-1\/fulltext."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients","volume":"386","author":"Musungaie","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_94","unstructured":"Robinson, J. (2022, January 19). Everything You Need to Know about the COVID-19 Therapy Trials. Available online: https:\/\/pharmaceutical-journal.com\/article\/feature\/everything-you-need-to-know-about-the-covid-19-therapy-trials."},{"key":"ref_95","first-page":"2766","article-title":"Acute Vertigo After COVID-19 Vaccination: Case Series and Literature Review","volume":"8","author":"Cocuzza","year":"2022","journal-title":"Front. Med."},{"key":"ref_96","first-page":"601","article-title":"Pharmacological Drugs Inducing Ototoxicity, Vestibular Symptoms and Tinnitus: A Reasoned and Updated Guide","volume":"15","author":"Cianfrone","year":"2011","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1472-6815-7-5","article-title":"Audiologic Monitoring of Multi-Drug Resistant Tuberculosis Patients on Aminoglycoside Treatment with Long Term Follow-Up","volume":"7","author":"Duggal","year":"2007","journal-title":"BMC Ear. Nose Throat. Disord."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S0030-6665(20)30774-X","article-title":"Audiologic Monitoring for Ototoxicity","volume":"26","author":"Campbell","year":"1993","journal-title":"Otolaryngol. Clin. North Am."},{"key":"ref_99","unstructured":"Campbell, K.C. (2007). Pharmacology and Ototoxicity for Audiologist, Thomson\/Delmar Learning. [1st ed.]."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1007\/s10067-007-0662-6","article-title":"Chloroquine Ototoxicity","volume":"26","author":"Bortoli","year":"2007","journal-title":"Clin. Rheumatol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1288\/00005537-198010001-00001","article-title":"Aminoglycoside Ototoxicity in the Human","volume":"90","author":"Fee","year":"1980","journal-title":"Laryngoscope"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1288\/00005537-198212000-00013","article-title":"Inner Ear Histopathology in Patients Treated with Cis-Platinum","volume":"92","author":"Wright","year":"1982","journal-title":"Laryngoscope"},{"key":"ref_103","unstructured":"Schuknecht, H. (1993). Pathology of the Ear, Lea & Febiger. [2nd ed.]."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3109\/00206098909081626","article-title":"Role of High-Frequency Audiometry in the Early Detection of Ototoxicity. II. Clinical Aspects","volume":"28","author":"Dreschler","year":"1989","journal-title":"Audiol. Off. Organ. Int. Soc. Audiol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3109\/00206098509078358","article-title":"The Role of High-Frequency Audiometry in Early Detection of Ototoxicity","volume":"24","author":"Dreschler","year":"1985","journal-title":"Audiol. Off. Organ. Int. Soc. Audiol."},{"key":"ref_106","first-page":"397","article-title":"Early Detection of Ototoxicity Using High-Frequency, Tone-Burst-Evoked Auditory Brainstem Responses","volume":"3","author":"Fausti","year":"1992","journal-title":"J. Am. Acad. Audiol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/00003446-199012000-00007","article-title":"High-Frequency Hearing Thresholds in Young Adults Using a Commercially Available Audiometer","volume":"11","author":"Frank","year":"1990","journal-title":"Ear Hear."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3109\/01050398009076360","article-title":"High Frequency Audiometry. Clinical Aspects","volume":"9","author":"Osterhammel","year":"1980","journal-title":"Scand. Audiol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/0090-8258(89)90519-2","article-title":"Evaluation of the Hearing Loss Associated with Cis-Platinum Treatment by High-Frequency Audiometry","volume":"33","author":"Kujansuu","year":"1989","journal-title":"Gynecol. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1044\/jslhr.4105.1061","article-title":"Aging and High-Frequency Hearing Sensitivity","volume":"41","author":"Wiley","year":"1998","journal-title":"J. Speech Lang. Hear. Res."},{"key":"ref_111","first-page":"123","article-title":"[Changes in transitory evoked otoacoustic emissions in chemotherapy with cisplatin and 5FU]","volume":"40","author":"Beck","year":"1992","journal-title":"HNO"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1053\/hn.1999.v121.a101567","article-title":"Effects of Cis-Platinum Chemotherapy on Otoacoustic Emissions: The Development of an Objective Screening Protocol. Third Place--Resident Clinical Science Award 1998","volume":"121","author":"Ress","year":"1999","journal-title":"Otolaryngol. Head Neck Surg."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0165-5876(93)90011-Q","article-title":"Evoked Otoacoustic Emissions and Pure Tone Threshold Audiometry in Patients Receiving Cisplatinum Therapy","volume":"25","author":"Zorowka","year":"1993","journal-title":"Int. J. Pediatric Otorhinolaryngol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-0028-1085137","article-title":"Cochlear Function and Otoacoustic Emissions","volume":"13","author":"Norton","year":"1992","journal-title":"Semin. Hear."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1121\/1.400897","article-title":"A Review of Otoacoustic Emissions","volume":"89","author":"Probst","year":"1991","journal-title":"J. Acoust. Soc. Am."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0030-6665(20)30770-2","article-title":"Ototoxicity of Loop Diuretics","volume":"26","author":"Rybak","year":"1993","journal-title":"Otolaryngol Clin. North Am."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Savitz, D.A., and Styka, A.N. (2020). Assessment of Long-Term Health Effects of Antimalarial Drugs When Used for Prophylaxis, The National Academies Press.","DOI":"10.17226\/25688"}],"container-title":["Audiology Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2039-4349\/12\/3\/25\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:03:48Z","timestamp":1760137428000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2039-4349\/12\/3\/25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,29]]},"references-count":117,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["audiolres12030025"],"URL":"https:\/\/doi.org\/10.3390\/audiolres12030025","relation":{},"ISSN":["2039-4349"],"issn-type":[{"value":"2039-4349","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,29]]}}}